Zhonghua zhong liu za zhi [Chinese journal of oncology]
-
Zhonghua Zhong Liu Za Zhi · Jul 2004
[Herceptin as a single agent in patients with HER2 overexpressing metastatic breast cancer].
To evaluate the efficacy and adverse reactions of Herceptin as a single agent in patients with HER2 overexpressing metastatic breast cancer. ⋯ Herceptin is an active agent for the patients with HER2 overexpressing metastatic breast cancer and the adverse events are well tolerated.
-
Zhonghua Zhong Liu Za Zhi · Jan 2004
[Treatment of recurrent malignant brain gliomas by surgical excision combined with biodegradable polymers of interstitial chemotherapy].
To investigate the effectiveness of treatment of recurrent malignant brain gliomas by surgical excision combined with biodegradable polymers of interstitial chemotherapy. ⋯ Surgical treatment combined with interstitial chemotherapy with biodegradable Vp-16 polymers improves the treatment result of recurrent malignant brain gliomas compared to surgery alone.
-
Zhonghua Zhong Liu Za Zhi · Sep 2003
[Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women].
To test the hypothesis whether polymorphism in estrogen-metabolizing genes, COMT and CYP17, impacts on the risk of breast cancer among Chinese women. ⋯ The allele encoding for low activity COMT, but not CYP17, may be a genetic risk factor for breast cancer among Chinese women.
-
Zhonghua Zhong Liu Za Zhi · Jul 2003
Randomized Controlled Trial Clinical Trial[High intensity focused ultrasound therapy combined with transcatheter arterial chemoembolization for advanced hepatocellular carcinoma].
To study high intensity focused ultrasound (HIFU) therapy combined with transcatheter arterial chemoembolization (TACE) in the treatment of patients with advanced hepatocellular carcinoma (HCC). ⋯ High intensity focused ultrasound therapy (HIFU) combined with transcatheter arterial chemoembolization (TACE), being better than TACE alone, may become one of the most effective treatments for patients with unresectable HCC.